|Bid||2.5600 x 800|
|Ask||2.6700 x 1000|
|Day's Range||2.5100 - 2.7500|
|52 Week Range||1.5000 - 5.7450|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 02, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.50|
Subscribe to Yahoo Finance Plus to view Fair Value for RNXT
In the interview, Dr. Michael Pishvaian discussed the trial's potential impact on the oncology community as well as how pancreatic cancer patients are treated.
RenovoRx Inc (NASDAQ: RNXT) announced interim data in the Phase 3 open-label TIGeR-PaC clinical trial investigating the company's first product candidate, RenovoGem, as a potential treatment option in locally advanced pancreatic cancer (LAPC). The interim analysis suggests a 6-month potential improvement in median overall survival with RenovoGem. The study compares treatment with RenovoTAMP versus standard-of-care systemic intravenous administration of gemcitabine and nab-paclitaxel, which has a
LOS ALTOS, Calif., March 08, 2023--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced promising interim data in the Phase III open label TIGeR-PaC clinical trial. The study is investigating the Company’s first product candidate, RenovoGem, as a potential treatment option in locally advanced pancreatic cancer ("LAPC").